LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Britain Courts Anthropic Amid US Defense Department Dispute 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
ATHLONE, Ireland, Nov. 23, 2016 -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will participate in a fireside chat at the Piper Jaffray Annual Healthcare Conference on Wednesday, November 30, 2016, at 1:30 p.m. ET at the Lotte New York Palace Hotel in New York, NY.
About Innocoll Holdings plc
Innocoll is a global, specialty pharmaceutical company with late stage development programs that is dedicated to engineering better medicines to help patients get better. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XARACOLL for the treatment of postoperative pain and COLLAGUARD (INL-003), a barrier for the prevention of post-surgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®.
Corporate: Pepe Carmona Chief Financial Officer (215) 983-3362 [email protected] Jeannie Sorenson, M.D. Vice President, Investor Relations (314) 458-7355 [email protected]
